HUTCHMED (China) Ltd, trading under the stock code 00013, saw its shares plummet by 7.49% in Friday's pre-market trading session. The significant drop comes on the heels of the company's announcement regarding its fiscal year 2025 guidance for oncology and immunology consolidated revenue.

In a statement released late Thursday, HUTCHMED updated its FY25 guidance for oncology/immunology consolidated revenue to a range of $270 million to $350 million. While the company did not provide the previous guidance figures in the announcement, the market reaction suggests that this update may be lower than investors' expectations.

The sharp decline in HUTCHMED's stock price reflects investors' concerns about the company's future revenue prospects in its key oncology and immunology segments. As a biopharmaceutical company focused on developing novel therapies in these areas, any adjustment to revenue projections can significantly impact investor sentiment. Analysts and shareholders will likely be closely monitoring the company's upcoming communications for further clarification on the factors influencing this guidance update and its potential implications for HUTCHMED's long-term growth strategy.